Abstract:
Jack Uldrich: In February, pSivida (Nasdaq: PSDV), an Australian-based company specializing in biomedical applications of nanotechnology, began trading on the Nasdaq as an American Depositary Receipt (ADR). In its first three months on Wall Street, it promptly fell from a high of $10 a share to just over $4.

Since that time, however, pSivida's stock has risen by more than 65%. It currently trades at around $7.

Will it continue to rise? I believe so, and I base that answer on three recent developments.